Sevenfact® (coagulation factor VIIa [recombinant]-jncw)

Sevenfact (rFVIIa) is covered for IV treatment and control of bleeding—and allowed as compendial prevention use—in patients aged ≥12 years with hemophilia A or B with inhibitors, but is not covered for children <12 or for other diagnoses/uses. Approval is time‑limited (initial 3 months, renewals 12 months) and requires meeting the policy’s coverage/safety criteria, adherence to specified weight‑based IV dosing, and documentation of diagnosis, age, weight, treatment/prevention rationale and response for initial and renewal requests.

"Treatment and control of bleeding episodes in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.